Brand Intelligence Graphcompany
Company Overview
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Business Model & Competitive Advantage
Regeneron's commercial portfolio is led by Dupixent (dupilumab) — a monoclonal antibody targeting IL-4 and IL-13 for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other allergic/inflammatory conditions. Dupixent has become one of the fastest-growing drugs in pharmaceutical history, with global sales exceeding $14B annually and ongoing label expansion into new indications. Other key products include Eylea (aflibercept) for macular degeneration and diabetic eye disease, Praluent (alirocumab) for high cholesterol, Kevzara (sarilumab) for rheumatoid arthritis, and Libtayo (cemiplimab) for certain skin and lung cancers.
Competitive Landscape 2025–2026
Regeneron trades on NASDAQ (REGN) with a market cap of approximately $55–70B. The company has one of the most productive R&D organizations in biotech — its VelociSuite technology enables rapid antibody and bispecific generation. In 2024, the FDA approved a Dupixent biosimilar competition timeline, creating a long-term revenue headwind that Regeneron is offsetting through new indications and pipeline development including Dupixent for COPD, oncology bispecifics, and obesity programs.
Recent Activity
View all →Key Differentiators
Market Leader
Regeneron Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $13.9B in revenue, Regeneron Pharmaceuticals operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Regeneron Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Regeneron Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Regeneron Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Regeneron Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →